natgillin/translations-raw huggingface dataset:
Effect of parecoxib (or its active metabolite valdecoxib) on the pharmacokinetics of other medicinal products 
Učinak parekoksiba (ili njegovog djelatnog metabolita valdekoksiba) na farmakokinetiku drugih lijekova
Placebo/valdecoxib treatment was also associated with a higher incidence of CV thromboembolic events versus placebo treatment, but this difference did not reach statistical significance. 
Liječenje placebom/valdekoksibom također je bilo povezano s većom incidencijom kardiovaskularnih tromboembolijskih događaja naspram liječenja placebom, ali razlika nije dosegla statističku značajnost.
Reconstitution solvents Acceptable solvents for reconstitution of Dynastat are: 
Otapala za rekonstituciju Prihvatljiva otapala za rekonstituciju Dynastata su:
The most common adverse reaction for Dynastat is nausea. 
Najčešća nuspojava Dynastata je mučnina.
Surgical wound complications (most involving the sternal wound) were observed at an increased rate with parecoxib/valdecoxib treatment. 
Komplikacije kirurške rane (većinom sternalne rane) bile su opažene u povećanoj stopi uz liječenje parekoksibom/valdekoksibom.
After reconstitution, the liquid should be a clear solution. 
Nakon rekonstitucije, tekućina mora biti bistra otopina.
In short-term studies (7 days), the incidence of endoscopically observed gastroduodenal ulcers or erosions in healthy young and elderly ( 65 years) subjects administered Dynastat (5-21%), although higher than placebo (5-12%), was statistically significantly lower than the incidence observed with NSAIDs (66-90%). 
U kratkotrajnim ispitivanjima (7 dana) incidencija endoskopski opaženih gastroduodenalnih ulkusa ili erozija u zdravih mladih i starijih ( 65 godina) ispitanika kojima se primjenjivao Dynastat (5-21%), iako viša nego uz placebo (5-12%), bila je statistički značajno niža od incidencije opažene uz nesteroidne protuupalne lijekove (66-90%).
There are no adequate data from the use of parecoxib in pregnant women or during labour. 
Nema odgovarajućih podataka o primjeni parekoksiba u trudnica ili tijekom porođaja.
It is recommended that Dynastat is used as soon as possible after it is mixed with solvent, although it may be stored if the instructions at the end of the leaflet are strictly followed. 
Preporučuje se primijeniti Dynastat što prije nakon miješanja s otapalom, iako ga se može čuvati ako se strogo pridržavate uputa na kraju Upute.
In reproduction toxicity tests, the incidence of post-implantation losses, resorptions and foetal body weight retardation occurred at doses not producing maternal toxicity in the rabbit studies. 
U testovima reproduktivne toksičnosti, incidencija postimplantacijskih gubitaka, resorpcije i smanjene fetalne tjelesne težine nastupila je pri dozama koje nisu bile toksične za majke u ispitivanjima na kunićima.
If you are given more Dynastat than you should you may experience side-effects that have been reported with recommended doses. 
Ako ste dobili više Dynastata nego što ste smjeli možete osjetiti nuspojave koje su opisane za preporučene doze.
Three of the six cardiovascular thromboembolic events in the placebo/valdecoxib treatment group occurred during the placebo treatment period; these patients did not receive valdecoxib. 
Tri od šest kardiovaskularnih tromboembolijskih događaja u skupini koja je primala placebo/valdekoksib nastalo je tijekom razdoblja primjene placeba; ovi bolesnici nisu dobili valdekoksib.
Valdecoxib is a selective COX-2 inhibitor within the clinical dose range. 
Valdekoksib je selektivni inhibitor COX-2 unutar kliničkog raspona doza.
Parecoxib should be used with caution in patients with hypertension. 
Parekoksib se mora primjenjivati s oprezom u bolesnika s hipertenzijom.
If, during treatment, patients deteriorate in any of the organ system functions described below, appropriate measures should be taken and discontinuation of parecoxib therapy should be considered. 
Ako se tijekom liječenja bolesniku pogorša funkcija bilo kojeg organskog sustava, kako je opisano u nastavku, moraju se primijeniti odgovarajuće mjere i razmotriti prekid terapije parekoksibom.
In healthy elderly subjects, the apparent oral clearance of valdecoxib was reduced, resulting in an approximately 40% higher plasma exposure of valdecoxib compared to healthy young subjects. 
U zdravih starijih ispitanika, vidljivi oralni klirens valdekoksiba bio je smanjen, što je dovelo do približno 40% veće izloženosti valdekoksibu u plazmi u usporedbi s onom u zdravih mladih ispitanika.
Steady state plasma concentrations of valdecoxib were reached within 4 days with twice daily dosing. 
Stanja dinamičke ravnoteže koncentracija valdekoksiba u plazmi bila su postignuta u roku od 4 dana uz doziranje dvaput dnevno.
NSAID use during the second or third trimester of pregnancy may cause foetal renal dysfunction which may result in reduction of amniotic fluid volume or oligohydramnios in severe cases. 
Primjena nesteroidnih protuupalnih lijekova tijekom drugog ili trećeg tromjesečja trudnoće može uzrokovati fetalni poremećaj funkcije bubrega koji može dovesti do smanjenja plodne vode ili oligohidramnija u teškim slučajevima.
The use of Dynastat, as with any medicinal product known to inhibit cyclooxygenase/prostaglandin synthesis, is not recommended in women attempting to conceive (see sections 4.3, 5.1 and 5.3). 
Primjena Dynastata, kao i bilo kojeg drugog lijeka za koji se zna da inhibira ciklooksigenazu/sintezu prostaglandina, ne preporučuje se u žena koje pokušavaju začeti (vidjeti dijelove 4.3, 5.1 i 5.3).
Reconstitution solvents This medicinal product must not be mixed with other medicinal products. 
Ovaj lijek ne smije se miješati s drugim lijekovima.
COX-2 inhibitors have been associated with increased risk of cardiovascular and thrombotic adverse events when taken long term. 
Inhibitori COX-2 povezani su s povećanim rizikom od kardiovaskularnih i trombotičkih štetnih događaja kad se uzimaju dulje vrijeme.
History of previous serious allergic drug reaction of any type, especially cutaneous reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme or patients with known hypersensitivity to sulfonamides (see sections 4.4 and 4.8). 
Prethodne ozbiljne alergijske reakcije na lijek bilo kojeg tipa, osobito kožne reakcije kao što su Stevens-Johnsonov sindrom, toksična epidermalna nekroliza, multiformni eritem ili bolesnici s poznatom preosjetljivošću na sulfonamide (vidjeti dijelove 4.4 i 4.8).
Dynastat may mask fever and other signs of inflammation (see section 5.1). 
Dynastat može prikriti vrućicu i druge znakove upale (vidjeti dio 5.1).
AUC and Cmax following twice daily administration is linear up to 50 mg IV and 20 mg IM. 
AUC i Cmax nakon primjene dvaput dnevno linearne su do doze od 50 mg i.v. i 20 mg i.m.
The reconstituted product should be used immediately (up to 24 hours if prepared aseptically), and should not be frozen or refrigerated. 
Pripremljeni lijek se mora odmah primijeniti (u roku od 24 sata ako je pripremljen aseptički) i ne smije ga se zamrzavati niti čuvati u hladnjaku.
or muscle tissue. 
mozak ili mišićno tkivo.
Solvent ampoules 2 ml ampoule: colourless neutral glass, Type I. 
Ampule s otapalom Ampule od 2 ml: bezbojno neutralno staklo, tipa I.
Parecoxib is suspected to cause serious birth defects when administered during the last trimester of pregnancy because as with other medicinal products known to inhibit prostaglandin, it may cause premature closure of the ductus arteriosus or uterine inertia (see sections 4.3, 5.1 and 5.3). 
Za parekoksib se sumnja da uzrokuje ozbiljne urođene defekte kad se primjenjuje tijekom posljednjeg tromjesečja trudnoće, zato što kao i drugi lijekovi za koje se zna da inhibiraju prostaglandin, može prouzročiti preuranjeno zatvaranje ductus arteriosusa ili inerciju uterusa (vidjeti dijelove 4.3, 5.1 i 5.3).
There is limited experience in other types of surgery, for example gastrointestinal or urological surgery (see section 5.1). 
Ograničeno je iskustvo s primjenom kod drugih vrsta operacija, na primjer gastrointestinalnih ili uroloških operacija (vidjeti dio 5.1).
A significantly (p=0.033) greater incidence of events in the cardiovascular/thromboembolic category was detected in the parecoxib/valdecoxib treatment group (2.0%) compared to the placebo/placebo treatment group (0.5%). 
Značajno (p=0,033) veća incidencija događaja u kardiovaskularnoj/tromboembolijskoj kategoriji otkrivena je u skupini liječenoj parekoksibom/valdekoksibom (2,0%) u usporedbi sa skupinom koja je primala placebo/placebo (0,5%).
Severe hepatic impairment (serum albumin <25 g/l or Child-Pugh score 10). 
Teško oštećenje funkcije jetre (serumski albumin <25 g/l ili Child-Pugh rezultat  10).
In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of NSAIDs, including Dynastat should be considered. 
U žena koje imaju problema sa začećem ili koje se podvrgavaju testiranju neplodnosti treba razmotriti prekid liječenja nesteroidnim protuupalnim lijekovima uključujući i Dynastat.
In those patients where the same IV line is to be used to inject another medicinal product, the line must be adequately flushed prior to and after Dynastat injection with a solution of known compatibility. 
U onih bolesnika u kojih se ista i.v. linija koristi za injiciranje drugog lijeka, linija se mora primjereno isprati prije i nakon injiciranja Dynastata otopinom poznate kompatibilnosti.
The mean (SD) duration of treatment was 4.1 (0.4) days for parecoxib and 4.2 (0.5) days for placebo, the range was 4-7 days for parecoxib and 4-9 days for placebo. 
Srednja vrijednost (SD) trajanja liječenja parekoksibom iznosila je 4,1 (0,4) dana, a 4,2 (0,5) dana za placebo, dok je raspon bio od 4 do 7 dana za parekoksib i od 4 do 9 dana za placebo.
On the basis of pharmacokinetics, no dose adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance of 30-80 ml/min. 
Na temelju farmakokinetike, nije potrebna prilagodba doziranja u bolesnika s blagim do umjerenim oštećenjem bubrega (klirens kreatinina od 30 do 80 ml/min).
Effects of other medicinal products on the pharmacokinetics of parecoxib (or its active metabolite valdecoxib) 
Učinci drugih lijekova na farmakokinetiku parekoksiba (ili njegovog djelatnog metabolita valdekoksiba)
Moderate hepatic impairment did not result in a reduced rate or extent of parecoxib conversion to valdecoxib. 
Umjereno oštećenje jetre nije dovelo do smanjenja brzine ili opsega konverzije parekoksiba u valdekoksib.
Reporting of overdose with parecoxib has been associated with adverse reactions which have also been described with recommended doses of parecoxib. 
Zabilježena predoziranja parekoksibom povezana su s nuspojavama koje su također bile opisane i uz preporučene doze parekoksiba.
In humans, studies demonstrated that valdecoxib metabolism is predominantly mediated via CYP3A4 and 2C9 isozymes. 
U ljudi, ispitivanja su pokazala da je metabolizam valdekoksiba pretežno posredovan izoenzimima CYP3A4 i 2C9.
Dynastat is preservative free. 
Dynastat ne sadrži konzervanse.
Solvent: clear and colourless solution. 
Otapalo: bistra i bezbojna otopina.
However, the reported rate of serious skin events appears to be greater for valdecoxib (the active metabolite of parecoxib) as compared to other COX-2 selective inhibitors. 
Međutim, zabilježena stopa ozbiljnih kožnih događaja čini se većom kod primjene valdekoksiba (djelatnog metabolita parekoksiba) nego drugih selektivnih inhibitora COX-2.
Patients with a history of sulfonamide allergy may be at greater risk of skin reactions (see section 4.3). 
Bolesnici koji u povijesti bolesti imaju alergiju na sulfonamide mogu biti u većem riziku od kožnih reakcija (vidjeti dio 4.3).
The most serious reactions occur uncommonly to rarely, and include cardiovascular events such as myocardial infarction and severe hypotension, as well as hypersensitivity events such as anaphylaxis, angioedema and severe skin reactions. 
Najozbiljnije reakcije se javljaju manje često ili rijetko, a uključuju kardiovaskularne događaje kao što su infarkt miokarda i teška hipotenzija, kao i reakcije preosjetljivosti poput anafilaksije, angioedema i teških kožnih reakcija.
The first perceptible analgesic effect occurred in 7-13 minutes, with clinically meaningful analgesia demonstrated in 23-39 minutes and a peak effect within 2 hours following administration of single doses of 40 mg IV or IM Dynastat. 
Prvi zamjetni analgetski učinak nastupio je nakon 7-13 minuta, uz klinički značajnu analgeziju nakon 2339 minuta i vršni učinak unutar 2 sata nakon primjene jednokratne doze Dynastata od 40 mg i.v. ili i.m.
The carcinogenic potential of parecoxib has not been evaluated. 
Kancerogenost parekoksiba nije ispitana.
SOLVENT AMPOULE LABEL : 2 ml 
NALJEPNICA AMPULE S OTAPALOM: 2 ml
No effects of parecoxib on male or female fertilities were found in rats. 
U štakora nisu pronađeni nikakvi učinci parekoksiba na plodnost mužjaka ili ženki.
As with all NSAIDs, parecoxib can lead to the onset of new hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of cardiovascular events. 
Kao i drugi nesteroidni protuupalni lijekovi, parekoksib može dovesti do nastanka hipertenzije ili pogoršanja postojeće hipertenzije, a oboje može pridonijeti povećanju incidencije kardiovaskularnih događaja.
There is limited clinical experience with Dynastat treatment beyond three days. 
Kliničko je iskustvo u liječenju Dynastatom duljem od tri dana ograničeno.
COX-2 is the isoform of the enzyme that has been shown to be induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. 
COX-2 je izooblik enzima za koji se pokazalo da ga induciraju proupalni podražaji i smatra se da je prvenstveno zadužen za sintezu prostanoidnih medijatora boli, upale i vrućice.
A hydroxylated metabolite of valdecoxib (via the CYP pathway) has been identified in human plasma that is active as a COX-2 inhibitor. 
Hidroksilirani metabolit valdekoksiba (putem CYP-a) koji je pronađen u ljudskoj plazmi aktivan je kao inhibitor COX-2.
Dissolve the powder completely using a gentle swirling motion and inspect the reconstituted product before use. 
Potpuno otopite prašak u bočici laganim kružnim pokretima i pregledajte rekonstituirani lijek prije primjene.
There is no clinical experience in patients with severe hepatic impairment (Child-Pugh score 10), therefore its use is contraindicated in these patients (see sections 4.3 and 5.2). 
Ne postoji kliničko iskustvo u bolesnika s teškim oštećenjem jetre (Child-Pugh rezultat 10) pa je stoga njegova primjena u ovih bolesnika kontraindicirana (vidjeti dijelove 4.3 i 5.2).
Dynastat contains 
Dynastat sadrži
Caution should be exercised when coadministering Dynastat with warfarin and other oral anticoagulants (see section 4.5). 
Potreban je oprez kad se Dynastat primjenjuje istodobno s varfarinom i drugim oralnim antikoagulansima (vidjeti dio 4.5).
If there is clinical evidence of deterioration in the condition of these patients, appropriate measures including discontinuation of parecoxib should be taken. 
Ako postoji klinički dokaz pogoršanja stanja tih bolesnika, moraju se poduzeti odgovarajuće mjere uključujući i prekid primjene parekoksiba.
• Use of Sterile Water for Injection for reconstitution is not recommended, as the resulting solution is not isotonic. 
• Primjena sterilne vode za injekciju ne preporučuje se za rekonstituciju, jer otopina koja se dobije nije izotonična.
Dynastat is supplied as a sterile, single unit-of-use vial that is packaged with a 2 ml ampoule with a fill volume of 2 ml sodium chloride 9 mg/ml (0.9%) solution (see below for various pack sizes and configurations) 
Dynastat se isporučuje kao sterilna bočica s jediničnom dozom za jednokratnu primjenu, pakirana s ampulom od 2 ml napunjenu volumenom od 2 ml otopine natrijevog klorida 9 mg/ml (0,9%) (vidjeti niže za različite veličine pakiranja i oblike).
However caution is advised when methotrexate is administered concurrently with NSAIDs, because NSAID administration may result in increased plasma levels of methotrexate. 
Međutim, preporučuje se oprez kada se metotreksat primjenjuje istodobno s nesteroidnim protuupalnim lijekovima, jer primjena nesteroidnih protuupalnih lijekova može uzrokovati povećane razine metotreksata u plazmi.
How to store Dynastat 
Kako čuvati Dynastat
Dynastat may be coadministered with opioid analgesics. 
Dynastat se može istodobno primjenjivati s opioidnim analgeticima.
Studies in types of surgery other than CABG procedures included patients with American Society of Anaesthesiology (ASA) Physical Status Class I-III only. 
Ispitivanja primjene kod drugih vrsta operacija osim postupaka ugradnje aortokoronarne premosnice uključila su samo bolesnike s fizikalnim statusom klase I-III prema Američkom anesteziološkom društvu (engl.
Dynastat should be used with caution in patients with moderate hepatic impairment (Child-Pugh score 7-9) (see section 4.2). 
Dynastat se mora primjenjivati s oprezom u bolesnika s umjerenim oštećenjem jetre (Child-Pugh rezultat 7-9) (vidjeti dio 4.2).
These decreases were not considered clinically important since Cmax of valdecoxib is comparable after IM and IV parecoxib administration. 
Ta se sniženja nisu smatrala klinički važnima budući da je Cmax valdekoksiba usporediv nakon i.m. i i.v. primjene parekoksiba.
There are no data indicating less overall adverse events associated with the use of parecoxib compared to placebo when used in conjunction with opioids. 
Nema podataka koji pokazuju da parekoksib, u usporedbi s placebom, ima ukupno manje štetnih događaja povezanih s njegovom primjenom kad se primjenjuje zajedno s opioidima.
Treatment with valdecoxib (40 mg twice daily for 7 days) produced a 3-fold increase in plasma concentrations of dextromethorphan (CYP2D6 substrate). 
Liječenje valdekoksibom (40 mg dvaput dnevno tijekom 7 dana) izazvalo je trostruko povećanje koncentracije dekstrometorfana (supstrata CYP2D6) u plazmi.
In a series of small, multiple dose studies in healthy young and elderly subjects, Dynastat 20 mg or 40 mg twice daily had no effect on platelet aggregation or bleeding compared to placebo. 
U nizu malih ispitivanja višekratne doze u zdravih mladih i starijih ispitanika, Dynastat u dozi od 20 mg ili 40 mg dvaput dnevno nije imao utjecaja na agregaciju trombocita ili krvarenje u usporedbi s placebom.
▪ If you have previously had an ulcer, bleeding or perforation of the gastrointestinal tract. 
• ako ste prethodno imali čir, krvarenje ili probušenje (perforaciju) probavnog trakta
Therefore, caution should be observed when coadministering Dynastat and medicinal products that are predominantly metabolised by CYP2D6 and which have narrow therapeutic margins (e.g. flecainide, propafenone, metoprolol). 
Stoga je potreban oprez kad se istodobno primjenjuju Dynastat i lijekovi koje pretežno metabolizira CYP2D6 i koji imaju uske terapijske granice (npr. flekainid, propafenon, metoprolol).
Concomitant use with opioid analgesics 
Istodobna primjena opioidnih analgetika
Some of these reactions have occurred in patients with a history of allergic-type reactions to sulfonamides (see section 4.3). 
Neke od tih reakcija nastale su u bolesnika koji su u povijesti bolesti imali alergijski tip reakcije na sulfonamide (vidjeti dio 4.3).
Based on the mechanism of action, the use of NSAIDs, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women. 
Na temelju mehanizma djelovanja, primjena nesteroidnih protuupalnih lijekova može odgoditi ili spriječiti rupturu folikula jajnika što se povezuje s reverzibilnom neplodnosti u nekih žena.
After IV or IM dosing of parecoxib, the elimination half-life (t1/2) of valdecoxib is about 8 hours. 
Nakon i.v. ili i.m. doziranja parekoksiba, poluvijek eliminacije (t1/2) valdekoksiba je oko 8 sati.
Chemical and physical in-use stability of the reconstituted solution have been demonstrated for up to 24 hours at 25C. 
Pokazalo se da je rekonstituirana otopina kemijski i fizikalno stabilna do 24 sata na temperaturi od 25C.
Adequate monitoring of methotrexate-related toxicity should be considered when coadministering parecoxib and methotrexate. 
Mora se razmotriti odgovarajući nadzor toksičnosti povezane s metotreksatom kad se parekoksib i metotreksat primjenjuju istodobno.
The difference in antiplatelet activity between some COX-1 inhibiting NSAIDs and COX-2 selective inhibitors may be of clinical significance in patients at risk of thrombo-embolic reactions. 
Razlika u antitrombocitnoj aktivnosti između nekih nesteroidnih protuupalnih lijekova koji inhibiraju COX-1 i selektivnih inhibitora COX-2 može biti od kliničkog značaja u bolesnika s rizikom od tromboembolijskih reakcija.
Elimination of valdecoxib is by extensive hepatic metabolism involving multiple pathways, including cytochrome P 450 (CYP) 3A4 and CYP2C9 isoenzymes and glucuronidation (about 20%) of the sulfonamide moiety. 
Valdekoksib se eliminira opsežnim metaboliziranjem u jetri pomoću brojnih metaboličkih puteva, uključujući izoenzime citokroma P450 (CYP) 3A4 i CYP2C9 i glukuronidaciju (oko 20%) sulfonamidnog dijela.
- If you have further questions, ask your doctor or nurse. 
- Ako imate dodatnih pitanja, obratite se liječniku ili medicinskoj sestri.
In young subjects, Dynastat 40 mg twice daily had no clinically significant effect on acetylsalicylic acid-mediated inhibition of platelet function (see section 4.5). 
U mladih ispitanika, Dynastat u dozi od 40 mg dvaput dnevno nije imao klinički značajnog učinka na inhibiciju funkcije trombocita posredovanu acetilsalicilnom kiselinom (vidjeti dio 4.5).
Patients with severe hepatic impairment have not been studied and therefore the use of Dynastat in patients with severe hepatic impairment is not recommended (see sections 4.2 and 4.3). 
Bolesnici s teškim oštećenjem jetre nisu ispitani i stoga se primjena Dynastata u bolesnika s teškim oštećenjem jetre ne preporučuje (vidjeti dijelove 4.2 i 4.3).
Coadministration of valdecoxib and lithium produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone. 
Istodobna primjena valdekoksiba i litija izazvala je značajno smanjenje serumskog klirensa (25%) i bubrežnog klirensa (30%) litija uz 34% veću serumsku izloženost u odnosu na primjenu samo litija.
Use of water for injection is not recommended, as the resulting solution is not isotonic. 
Primjena vode za injekcije se ne preporučuje, jer dobivena otopina nije izotonična.
However, for elderly patients weighing less than 50 kg, treatment should be initiated with half the usual recommended dose of Dynastat and reduce the maximum daily dose to 40 mg (see section 5.2). 
Međutim, u starijih bolesnika tjelesne težine manje od 50 kg, liječenje se mora započeti polovicom uobičajeno preporučene doze Dynastata i sniziti maksimalnu dnevnu dozu na 40 mg (vidjeti dio 5.2).
Do not use Dynastat if you currently have a gastric or intestinal ulcer or gastrointestinal bleeding 
Nemojte primjenjivati Dynastat ako trenutno imate čir na želucu ili crijevima ili krvarite u probavni trakt
In animals, administration of prostaglandin synthesis inhibitors, including parecoxib, has been shown to result in increased pre- and post-implantation loss and embryo-foetal lethality (see sections 5.1 and 5.3). 
Ispitivanja na životinjama pokazala su da primjena inhibitora sinteze prostaglandina, uključujući i parekoksib rezultira u povećanom preimplantacijskom i postimplantacijskom gubitku i letalitetu embrija i fetusa (vidjeti dijelove 5.1 i 5.3).
Dynastat had no effect on acetylsalicylic acid-mediated inhibition of platelet aggregation or bleeding times. 
Dynastat nije imao učinka na inhibiciju agregacije trombocita posredovanu acetilsalicilnom kiselinom ili na vrijeme krvarenja.
2 ml solvent ampoule contains sodium chloride, hydrochloric acid, sodium hydroxide and water for injection. 
Ampula s 2 ml otapala sadrži natrijev klorid, kloridnu kiselinu, natrijev hidroksid i vodu za injekciju.